251 BALLARDVALE ST, WILMINGTON, MA
Annual Report to Security Holders
Charles River Laboratories Announces Planned Divestiture of CDMO and Cell Sol...
CFO Appointment - Glenn Coleman Named Chief Financial Officer
Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
Earnings Release
CEO Transition - James C. Foster Steps Down; Birgit Girshick Appointed
Reg. FD
Other Events
FY 2024
Q3
Q2
Q1
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Specialized Disclosure Report
Submission Upload
Correspondence